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Methods: Drawing on an independent evaluation of a multi-site improvement programme (Safer 10
Clinical Systems), we combined a qualitative study of participating teams' experiences and 11 perceptions of measurement with expert review of measurement plans and analysis of data 12 collected for the programme. Multidisciplinary teams of frontline clinicians at nine UK NHS sites took 13 part across the two phases of the programme between 2011 and 2016. 14 Results: Developing and implementing a measurement plan against which to assess their 15 improvement goals was an arduous task for participating sites. The operational definitions of the 16 measures that they selected were often imprecise or missed important details. Some measures used 17 by the teams were not logically linked to the improvement actions they implemented. Regardless of 18 the specific type of data used (routinely collected or selected ex-novo), the burdensome nature of 19 data collection was underestimated. Problems also emerged in identifying and using suitable 20 analytical approaches. 21
Conclusion: Measurement is a highly technical task requiring a degree of expertise. Simply leveraging 22
individual clinicians' motivation is unlikely to defeat the persistent difficulties experienced by clinical 23 teams when attempting to measure their improvement efforts. We suggest that more structural 24 initiatives and broader capability-building programmes should be pursued by the professional 25 community. Improving access to, and ability to use repositories of validated measures, and 26 increasing transparency in reporting measurement attempts, is likely to be helpful. 27 28 29 INTRODUCTION 1 Measurement is essential to improving quality and safety in healthcare processes and outcomes. 1 2 2
Yet the available evidence suggests that many quality improvement projects may fail to generate 3 reliable or useful data because of challenges in measurement, data collection, and interpretation. 3-6 4 Characteristic problems include missing data or insufficient data points; insufficient baseline periods; 5 poorly chosen, unclear, or changing sampling strategies; poorly annotated data; failure to verify data 6 entry; and poorly chosen or executed analytic strategies. 7 8 Benn and colleagues found many of 7 these problems when teams sought to implement data collection and analysis systems in local 8 settings as part of a large-scale quality improvement programme. 9 Similarly, a study of a national 9 system for surveillance of healthcare-associated infections 10 found variability in how well intensive 10 care units designed their data collection systems and in how they interpreted data. 11
Failure to produce reliable data about improvement and to interpret it correctly is an important 12 challenge for quality improvement, limiting the inferences that can be made about the success or 13 otherwise of improvement interventions, as well as eroding confidence in the evidence-base for 14 improvement. 11 This problem manifests in summative evaluations but also affects programmes while 15 they are running, when data has potential to be used formatively to optimise the improvement 16 effort. 17
Some of the problems in measuring improvement are likely to be linked to ongoing controversies 18 about the relevant dimensions of quality and safety and the prioritisation of different types of 19 measures, including, for example, the process versus outcome debate. 8 9 12 Other problems are likely 20
to be more mundane, relating, for example, to issues in establishing data collection systems. 10 21 Importantly, the literature suggests that some problems may also be linked to ownership: studies of 22 measurement have tended to focus on quality measures generated externally to clinical teams (e.g. 23 by regulators or payers), which clinicians may not perceive as directly relevant to their everyday 24 concerns. One suggestion is that clinicians may lack engagement because they perceive externally 25 imposed measures as having little or no relevance to their clinical work and as little more than an 26 administrative burden. 8 Yet little evidence exists on what happens when clinical teams themselves 27 choose their own measures (rather than having to use those selected externally) and design and 28 implement data collection systems that they see as fitted to their own local circumstances. A well-29 characterised account of responses to such an opportunity would be very useful. 30
In this article, we use data from a mixed-methods independent evaluation of a nine-site UK patient 31 safety improvement programme to report on clinical teams' experiences of using locally selected 32 measures. We aimed specifically to describe their experiences of planning and conducting 33 measurement activities, collecting data, and analysing and interpreting data for their improvement 34
projects. 35
METHODS

36
The Safer Clinical Systems improvement programme 37 The study we report is based on data from an independent evaluation of a patient safety 38 improvement programme run in the UK, which used an approach known as Safer Clinical Systems. 7 39
Based on methods of risk management and improvement used in other hazardous industries, the 1
Safer Clinical Systems approach seeks to enable organisations to make improvements to local clinical 2 systems and pathways using a structured methodology for identifying risks and for modifying or re-3 engineering systems to control risk and enhance reliability. 7 13 It involves a series of steps in which 4 teams define a clinical pathway and its context; do a detailed diagnostic assessment of the pathway 5
to identify risks and hazards; assess and select options for change and develop an action plan to 6 implement them; and undertake system improvement cycles involving implementation, evaluation 7 of progress against a measurement plan, and revision of interventions. 8
Measurement is a key element of Safer Clinical Systems. During the course of the programme, 9
participating teams were expected to: 1) develop a detailed measurement plan to set out outcome 10 and/or process measures that were appropriate for collecting useful data; 2) establish data 11 collection systems; and 3) analyse and interpret their data using Statistical Process Control (SPC) 12 (Box 1). 13
Box 1 14
A distinctive feature of Safer Clinical Systems is that it does not try to impose predefined solutions, 15
but instead seeks to help organisations develop their own capacity to detect and address 16 weaknesses in their systems, and to measure and report their improvement outcomes. It does so by 17 offering training on a range of improvement tools and techniques (including how to measure for 18 improvement), and emphasising the need to engage local staff (clinical and managerial) in 19 improvement attempts. 20
Funded by an independent charity (The Health Foundation), the programme was run in a total of 21 nine UK hospitals in two phases: the main phase, which ran 2011-14 and included eight sites, and 22 the extension phase, which ran 2014-16 and included six sites (five of the original sites plus an 23 additional one that had not taken part in the main phase). Each of the nine hospitals taking part in 24 the programme used the Safer Clinical Systems approach to proactively assess risks and hazards in 25 their clinical pathways and to develop effective risk-control interventions (Table 1) . 26
In the main programme phase, participating sites received training and guidance, and were 27 monitored in their progress, by a dedicated programme support team. Support on measurement 28
included approximately one day of training on principles of measuring improvement, statistical 29 process control (SPC), and use of software for capturing their data and generating charts. In the 30 extension phase, teams were expected to use the Safety Clinical Systems approach on their own, 31
without the support and control that characterised the main phase. 32 Table 1  33 Programme evaluation 34 We undertook an independent evaluation of the Safer Clinical Systems programme using a mixed-35 method design. We combined a qualitative study, which aimed to describe how participating teams 36 experienced taking part in the Safer Clinical Systems programme, with expert review of 37 measurement plans and analysis of data collected for the programme. The study was granted ethical 38 approval by the [name omitted] Research Ethics Committee [number reference omitted]. 39
Qualitative study 1
We conducted semi-structured interviews with members of the participating teams and 2 unstructured ethnographic observations of teams' activities related to programme participation. 3 Particular effort went into capturing how teams undertook tasks relating to measurement (e.g. 4
identified and selected their quality measures, and developed and implemented a measurement 5 plan to assess the impact of their improvements). We were also interested in characterising the 6 challenges and hurdles faced by the teams in doing so. 7
Observations and interviews were conducted by non-clinical researchers who were members of the 8 evaluation team. Interviews were conducted in person or on the phone, were recorded digitally, and 9 transcribed verbatim. All interviewees signed an informed consent form. Observations were 10 unstructured and included routine clinical activities, team meetings, and informal chats with 11 relevant staff. Extensive field notes were taken during visits, and researchers were then debriefed by 12 other members of the evaluation team on return from visits. 13
Expert review of measurement plans 14
All the measurement plans prepared by the participating teams were reviewed by one author (XX), 15
who is a specialist in measurement for improvement and an expert in SPC. Published checklists 16
aimed at improving the quality of measurement were used as review criteria. 3 14 The level of 17 information on each step of the measurement process provided by teams was deemed unclear if it 18
was not sufficient for author XX to know how to repeat the measurement process. The reviews of 19 these plans were used for evaluation purposes (e.g. to assess the quality of the plans) and to provide 20 formative feedback to the participating teams. This feedback was provided to each team through ad 21 hoc coaching sessions, led by author XX and the programme support team in the main phase, and 22
author XX alone in the extension phase. Up to two such sessions, conducted by telephone, were 23 offered to each team. 24
Towards the end of each phase of the programme, XX reviewed and independently analysed the raw 25
data from a selection of the participating sites (four sites in the main phase and four sites in the 26 extension phase). We initially sought to select sites that would ensure the greatest diversity of 27 projects. However, some sites did not produce data, or did not produce data in a form suitable for 28 analysis, and could not be included. Table 1 illustrated the four sites in each phase that had their raw 29 data subject to independent SPC analysis. 30
Data analysis and synthesis 31
Analysis of the qualitative data was based on the constant comparative method, inductively 32 generating thematic categories, and using the literature on measurement and quality improvement 33 as sensitising concepts. 15 We first analysed data site-by-site to ensure that it was understood in 34 terms of relevant context. Then, for each site, we integrated qualitative data and findings from the 35 expert review to produce a comprehensive and in-depth picture of sites' experiences of 36 measurement. Finally, we conducted cross-site analysis in order to develop higher-level concepts 37 and broader learning on measurement. 38
RESULTS
1
Across the two phases of the study (main and extension), the qualitative evaluation study involved 2 862 hours of observation and 143 interviews (Table 2) covering all aspects of the programme (not 3 just measurement). The participating site teams specified, between them, a total of 67 measures 4 that they planned to use to monitor their processes before and after introduction of their risk-5 control interventions. The data for 49 of these measures -which were sourced from four of the 6 eight sites participating in the main phase, and from four of the six sites participating in the 7 extension phase -were independently analysed by the evaluation team (Table 2) . 8 Table 2  9 The clinical teams participating in the programme typically comprised a clinical lead (often a senior 10 physician), a project manager, others from a clinical or managerial background, and an executive 11 sponsor (a senior individual who reported to the board but was not involved in day-to-day running 12 of the project). The participating sites varied in the extent to which they enjoyed active support from 13 executive or non-executive board members, and from other clinicians; the interaction of the work 14 with infrastructure such as large IT system projects; a pre-existing audit culture and organisational 15 capability for managing complex data; and the resources available to the teams, including release of 16 staff to undertake project work. In the account below, we offer an analysis of measurement-specific 17 issues, and specifically on teams' ability to: 1) manage the tasks associated with developing 18 measurement plans; 2) establish and use reliable data collection systems; and 3) analyse and report 19 data in appropriate ways. Our analysis is focused on drawing out generalisable learning across the 20 programme, and does not seek to compare/contrast sites. 21
Developing a detailed measurement plan 22 The measurement plans that the teams were asked to develop were intended to identify and define 23 suitable measures in advance of any improvement interventions being implemented, and to specify 24 a sampling and analytical strategy. In the main phase (in which participating teams received 25 dedicated measurement support and guidance) all teams produced a measurement plan document; 26 in the extension phase, two out of the six teams did so. When no measurement plan was available, 27 the evaluation team assessed any written material provided by the teams that included elements of 28 measurement planning. Our review of the measurement plans (or related documents) indicated that 29 most demonstrated great enthusiasm but also multiple problems -here, we describe six. 30
The first problem was the over-ambitious nature of the plans. Several teams initially identified very 31 many measures (up to 15 in some cases) that were highly diverse in character. Given the formative 32 nature of the evaluation, these sites were asked to reduce the number of measures in their final 33 measurement plans to five or six, and to concentrate their efforts on those ( imprecise, lacked important details, or were difficult to understand by those outside the project 7 team. For example, some sites used compliance with a care bundle (e.g. medication reconciliation or 8 review) as a measure, but did not always specify the operational definition of the individual 9
components of the bundle. One team used a measure labelled as "Number of patients […] who have 10 their medicines 100% correct at 24 hours" without specifying how staff should ascertain that 11 medicines were correct. Similarly, terms such as "delay", "error", "time zero", and "baseline" were 12 not fully defined, leaving room for different interpretations between observers and over time. When 13 sites reported that some data were "not applicable" to certain measures, they did not always give a 14 reason for this. 15
Different names are used to refer to the same measures in this document when compared 16
with the others, and also in different parts of the same document. For example, the following 17 two measure names seem to be used interchangeably: "% of patients on EAU [emergency 18
assessment unit] who have all their medicines correct at 24 hours" and "Accuracy of 19 prescription at 24h on EAU". (Evaluation team's review of the measurement plan, extension 20 phase) 21
The third problem was that some measures selected by the teams were insufficiently sensitive to 22 capture the spectrum of improvements sought by the sites. For example, one site's definition of 23 compliance with its medication reconciliation bundle stated that all ten elements of care in the 24 bundle should be in place. Even if nine elements of the bundle were in place and one was not, the 25 patient's care was deemed non-compliant. Bundles should usually include fewer elements (three to 26 five), 16 17 suggesting perhaps suboptimal design of the bundle, but also indicating that full 27
compliance was unrealistic and that use of this measure might fail to detect potential 28 improvements. 29
Fourth, specification of sampling procedures was typically weak, and it was often unclear what 30 procedure was to be used for random selection. Inclusion and exclusion criteria necessary for 31
determining who or what should be counted were often unclear. For instance, one site in the 32 extension phase reported in their measurement plan that "each week a random sample of 5 patient 33 case notes should be selected for admission, transfer and discharge", without specifying how such 34 random sampling should be done. If, for example, staff selected patients randomly from physical 35 stacks of notes, bias might be introduced if some patients' notes were unavailable. 36
The fifth problem was that some selected measures were not logically linked to the improvement 37 actions they implemented. For example, one site opted to measure the average proportion of 38 patients going to the operating theatre with a completed perioperative care plan, but then struggled 39 to implement an intervention that would increase completion of the plans. In this site, due to 40 uncertainty about the renewal of the hospital IT contract, it was difficult to make available 41 documents relevant to surgery on the trust's IT system at the operation stage, and this improvement 1 action was therefore abandoned. Thus, although the site recorded an improvement between the 2 two measurement periods (from 65% to 78% of patients with a complete plan), it was difficult to 3 attribute the site's improvement to its Safer Clinical Systems project. 4
Sixth, in general the measurement plans produced by the teams did not look sufficiently far ahead. 5
For example, the plans did not contain the specifics of how the data would be analysed, thus 6
impacting on important considerations such as the appropriate length of the baseline and how much 7 data over what period would be needed to establish whether an improvement had been made. 8
Most plans did not touch on who was responsible for taking action for improvement based on the 9 findings of the analysis, or on embedding measurement in routine care. 10
Collecting data 11
Interviews and observations showed that teams generally struggled to set up and run data collection 12 systems, and that running the systems consumed a huge amount of time and resource at several 13 sites. Some challenges were related to teams' decisions to use entirely new measures for the first 14 time (including "home-grown" measures). Some teams started by using lengthy, unwieldy manual 15 data collection forms that were sometimes amended or abandoned after a short time. In other 16
cases, teams used routinely collected data, but these data were often not as clean or well set up as 17
originally anticipated, and often required extensive effort to bring them up to a standard suitable for 18 use. 19
It's been a nightmare actually… data. One team struggled to get reliable data collection at weekends. In one site, a special form that 36 was supposed to be used for data collection was not consistently used, with data instead collected in 37 a notebook or on odd pieces of paper in non-standard formats. In another example, attempts to 38 collect data from doctors at the end of night shifts was met with difficulty, as the physicians were 39 tired and wanted to finish their clinical tasks before going off duty. 40 A further challenge was that teams did not reliably collect baseline data before they introduced 1 interventions aimed at improvement. In part, this was because once the participating sites became 2 aware of the many (and, in some cases, severe) hazards threatening patient safety in their clinical 3 systems through use of the Safer Clinical Systems diagnostic tools, they were understandably eager 4 to address these hazards quickly. Accordingly, some sites proceeded to implement improvement 5 actions before measurement had started. The consequent absence of a baseline period, while well-6 justified in terms of addressing risk, meant that it was difficult to demonstrate that any 7 improvement was attributable to the programme or indeed that the risk was now well-controlled. 8
Analysing and interpreting data 9 The teams' ability to conduct SPC analysis to present and interpret their data was highly variable. 10
Some sites succeeded in analysing data on their key process measures regularly and producing high 11 quality reports. For example, one site recorded changes in clerked weekday in-hours and out-of-12 hours admissions or senior reviews within four hours of admission; another site analysed the 13 percentage of patients who had the correct medications at 24 hours after admission. These analyses 14 were undertaken to a high level of competence and accuracy. Other sites, however, struggled with 15
undertaking appropriate analysis of their data. 16
One reason for these differences lay in the variable mix of skills and experience in participating 17 teams. One team included an academic advisor who had expertise in measurement and experience 18
working with the hospital's Quality Improvement Directorate. Other sites lacked such a skillset: 19
It would have been great to have someone with data analysis skills, or someone from our 20 informatics team who was dedicated to [our project]. We've used up a lot of our teams' time 21
learning where different bits are kept. (Interview, main phase) 22
In some cases, appropriate analysis was not possible because of basic weaknesses in the measures 23 or data recording, for example, when the definitions used were so poorly specified that it was not 24 clear exactly what was being measured. For instance, in measuring the time from admission to the 25 diagnostic test being done, one team recorded the time but not the date of the test. It was therefore 26 impossible to distinguish whether the test had taken, for example, four or 28 hours. 27
Analysis was also severely hindered by missing data. For example, in one site, missing data for one 28
week meant that it was not possible to complete SPC analysis of one of their key measures. This 29 site's measurement planning did not include any strategies for minimising or mitigating missing data, 30 a common theme across the sites. In another site, data collection was frustrated by the small 31 number of patients meeting the eligibility criteria, complicating any attempts to make valid 32 inferences or draw conclusions about the impact of the intervention. Since very few measurement 33 plans included an advance plan for the type of analysis, many sites failed to exploit some available 34 support tools that would have proved highly beneficial. For example, when using a p-chart, 18 tables 35 could be used to identify an appropriate frequency of data collection and a subgrouping strategy (i.e. 36
weekly percentages versus monthly or other period) to make sure that the chart is sensitive enough 37 to be useful. 19 38 Analysis and interpretation were sometimes flawed: we saw evidence of sites assuming that their 39 data provided evidence of improvement, but such interpretations were not always backed up by 40 sound statistical analysis. One site reported improvement on a measure from around 75% to just 1 under 90%, but no statistical analysis was presented to back up this claim. Visual inspection of a time 2 series chart seemed to show a potentially unstable process; it was therefore impossible to draw 3 accurate conclusions from such statements. Another site presented data for two measures that 4 showed possible evidence of improvement, but without statistical process control analysis it was not 5 possible to conclude whether this was true improvement in the process. 6 DISCUSSION 7
Our study suggests that improvement programmes that emphasise local ownership and local 8 selection of measures, such as Safer Clinical Systems, may not escape the pervasive challenges of 9
high quality measurement. Teams may struggle to produce a high quality measurement plan, to 10 provide clear definitions of their measures and data, or to complete data collection and analysis 11
reliably. Participating teams often selected unreliable or inappropriate measures, some of them 12 "home-grown", indicating that an emphasis on local ownership of measures is not always 13 compatible with the need to use the kind of validated measures that are most suited to producing 14 sound, credible evidence. The range of skills required to collect and analyse data was not generally 15 sufficient in most teams, despite some training being provided by the programme. These challenges 16
were pervasive across sites irrespective of the specific data, measures, and analytical approach 17
adopted -to the point that they may indicate a systemic problem. 7 18
We did not aim to explain differences across sites, nor to identify the contextual factors promoting 19 or inhibiting effective measurement in each setting, but our analysis does allow insight into 20 widespread challenges that may hamper teams' measurement efforts. The effective execution of 21 measurement across the lifespan of a quality improvement initiative requires expertise in a range of 22 technical activities: selecting measures, high fidelity data collection, statistical analysis, and 23
interpretation of results. The consequences of decisions made in the early stages of designing 24 measures may not become apparent until the middle or end of an improvement initiative, by which 25 time it may be too late to secure high quality data. Experience of working on several improvement 26 initiatives provides valuable insights into the constraints of data access and collection in healthcare 27 systems, and enables more realistic planning for future initiatives. This study highlights the tendency 28
for teams without such knowledge and experience to underestimate the challenges they may face in 29 enacting their measurement plans, and the resulting mismatch in skills and time dedicated to 30 measurement activities. All of this indicates the need for clinical teams to access dedicated capability 31
and capacity for measurement. The optimal approach to building or sourcing this capability and 32 capacity across local and national health systems is not clear, and it seems likely this will take 33 considerable time to achieve. 20 Our study does suggest that it is not realistic to assume that brief 34 training interventions and manuals will be enough to bring most clinical teams fully up to speed. 35
As well as measurement-specific issues, broader characteristics of the organisational setting, well 36 established in the literature as influencers of success in improvement, played a role in enabling or 37
hindering the teams' ability to measure effectively. [21] [22] [23] This complexity means that narrow 38
interventions are unlikely to be sufficient to improve the quality of measurement in quality 39
improvement. Some relatively simple forms of support might, however, be helpful. Existing 40 repositories of validated measures, such as the US-based AHRQ Measures Clearing House, are 41 important resources that may not be having their desired impact; teams in this study did not 42 reference such repositories in their plans. This may be due to a lack of awareness that such 1 repositories exist, limitations in the coverage and relevance of repositories for specific improvement 2 initiatives, and deficits in technical skills and knowledge needed to use centrally constructed 3 measure definitions. Further research is needed to understand these issues, and to support 4 healthcare professionals to capitalise on existing resources. 5
Improving access, and ability to use, repositories of validated measures could go some way to 6 addressing some of the challenges we identify. Increasing transparency in reporting (e.g. publishing 7
failed measurement attempts and inappropriate endpoints) might serve the same purpose while 8 enhancing the evidence base for measurement. Yet, such actions are likely to have limited impact 9 without a broader programme of measurement capability-building at a system level. The definitions 10 of measures will always need to be interpreted and implemented in local systems to account for 11 variation in processes across settings. 10 Increased capability in measurement is necessary for staff at 12 all levels to understand and act in response to measures. 13
Our study of measurement does have limitations. Although we used established techniques (e.g. 14 integrating multiple sources of data and collecting data at multiple points in time) to improve the 15 rigour and generalisability of our analysis, our study is limited the fact that we have examined a 16 specific improvement programme, which took place in hospitals only and was focused on the 17 identification of risks in clinical systems. 18
The potential benefits of robust measurement in improvement initiatives are clear. Yet it is not clear 19 how best to realise those benefits in practice. Countering the problems of measurement that hinder 20 quality improvement projects is vital, not least because they undermine the credibility of the 21 enterprise and diminish the prospect that clinicians will take the results seriously in future 22 improvement efforts. Unfortunately, using a local ownership approach does not seem to provide an 23 escape from these problems. We conclude that, in driving improvement, the data (and the data 24 source) need to be seen as credible by potential participants, while at the same time not too irksome 25 or burdensome to collect, 8 but how to achieve an optimal balance between expert input and local 26 ownership requires further examination. Future research should focus on understanding how 27 measurement can be planned, executed, and drawn on to best support improvement in quality of 28 care for patients. Different models for measurement, aiming to address the challenges highlighted in 29 this study, should be evaluated. Such models could include those that involve more extensive 30 training of NHS personnel, loaning of information analysts to improvement teams, resources to 31 support better planning and execution of measurement, and provision of consultancy expertise. 32 33
Box 1: Measurement in the Safer Clinical Systems approach 1
Measurement is a key element of the Safer Clinical Systems approach, which emphasises local ownership and local selection of measures for the monitoring of improvement. The approach does not recommend or impose any external measures, though it does recommend that Statistical Process Control (SPC) be used as a means of monitoring and analysis of data.
SPC is an approach to understanding and acting on variation observed in measured properties of a system. In this approach, data is used to gain insight into how a healthcare system or process is performing, and how this performance is changing over time. These insights inform actions on the system, targeted at causes of poor performance. Continuing analysis is used to understand whether these actions have led to improvement.
Control charts are the main analytical tool used in SPC. A control chart shows a time series of how the measure varies over time. The centre line represents typical performance of the process or outcome that the team is seeking to improve. Control limits (dotted lines parallel to the centre line) show the degree of variation that is to be expected assuming that the process or outcome being measured has not changed. SPC provides sets of rules that are used to assess a time series for the presence of special cause variation -evidence that performance has changed. Many missing data on two measures, and data on two further measures was difficult to interpret due to poor quality presentation.
 Four measures reported in safety set.  No formal measurement plan was developed.  Operational definitions were initially unclear but were clarified later in the project.  Data quality was poor in places leading to difficulties in interpretation.
Cedartree
Improve safety and effectiveness of the transfer of care between daytime and out-of-hours clinical teams.
Refine the Safety Case approach, explore its scalability and its potential application to a complex pathway (i.e. surgery).
Yes, data from 5 measures
No (no data were collected)  Five measures reported in safety set. 
The large amount of data collected by this team placed considerable strain on resources. 
The team lacked experience to access and use the relevant data and IT systems, and initially struggled balancing desired data collection against available staff time, leading to some missing data.  Operational definitions of some measures were unclear. 
Only one month of baseline data was available, making it hard to evaluate improvement.
The project stalled after the diagnostic phase. No risk controls were implemented and no measurement plan was in place.
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